Close

Cantor Fitzgerald Downgrades Alcobra Ltd. (ADHD) to Hold

Go back to Cantor Fitzgerald Downgrades Alcobra Ltd. (ADHD) to Hold

Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study

September 28, 2016 8:01 PM EDT

TEL AVIV, Israel, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it has received verbal notice from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on its Investigational New Drug (IND) applications for MDX in ADHD and Fragile X Syndrome. The clinical hold affects Alcobras ongoing Phase III... More